Acquisition of paclitaxel resistance via PI3K-dependent epithelial-mesenchymal transition in A2780 human ovarian cancer cells

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1113-1118

  Du, Fangfang ^a   Wu, Xiaohong ^a   Liu, Yanjun ^a   Wang, Teng ^a   Qi, Xiaowei ^a   Mao, Yong ^a   Jiang, Li ^a   Zhu, Yifei ^a   Chen, Yun ^a   Zhu, Ruiyu ^a,b   Han, Xiaofeng ^a   Jin, Jian ^a,b   Ma, Xin ^a,b   Hua, Dong ^a  

^a JIANGNAN UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

Author keywords

Chemoresistance; Epithelial to mesenchymal transition; Ovarian cancer; Paclitaxel

Indexed keywords

PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE;

ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RESISTANCE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN A2780; CELL STRUCTURE; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG RESISTANCE; ENZYME ACTIVITY; ENZYME INHIBITION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; MOLECULAR BIOLOGY; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED; WOUND HEALING;

EID: 84880624601     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2567     Document Type: Article

References (24)

1. Vergara D, Merlot B, Lucot JP, et al: Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 291: 59-66, 2010.
2. Kajiyama H, Shibata K, Terauchi M, et al: Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31: 277-283, 2007.
3. Jia L, Zhang S, Ye Y, et al: Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Lett 326: 176-182, 2012.
4. Rosano L, Cianfrocca R, Spinella F, et al: Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res 17: 2350-2360, 2011.
5. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
6. Shah AN, Summy JM, Zhang J, Park SI, Parikh NU and Gallick GE: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol 14: 3629-3637, 2007.
7. Rho JK, Choi YJ, Lee JK, et al: Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line. Lung Cancer 63: 219-226, 2009.
8. Hiscox S, Jiang WG, Obermeier K, et al: Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and involves modulation of β-catenin phosphorylation. Int J Cancer 118: 290-301, 2006.
9. Zhou Q, Zeng R, Xu C, et al: Erbin inhibits TGF-β1-induced EMT in renal tubular epithelial cells through an ERK-dependent pathway. J Mol Med (Berl) 90: 563-574, 2012.
10. Conti B, Minutolo A, Arciello M and Balsano C: Are Hedgehog and Wnt/β-catenin pathways involved in hepatitis C virus-mediated EMT? J Hepatol 58: 636-637, 2012.
11. Radisky DC and Bissell MJ: NF-κB links oestrogen receptor signalling and EMT. Nat Cell Biol 9: 361-363, 2007.
12. Xu X, Zhou Y, Xie C, et al: Genome-wide screening reveals an EMT molecular network mediated by Sonic Hedgehog-Gli1 signaling in pancreatic cancer cells. PLoS One 7: e43119, 2012.
13. Lim M, Chuong CM and Roy-Burman P: PI3K, Erk signaling in BMP7-induced epithelial-mesenchymal transition (EMT) of PC-3 prostate cancer cells in 2- and 3-dimensional cultures. Horm Cancer 2: 298-309, 2011.
14. Li Y, Maitah MY, Ahmad A, Kong D, Bao B and Sarkar FH: Targeting the Hedgehog signaling pathway for cancer therapy. Expert Opin Ther Targets 16: 49-66, 2012.
15. Larue L and Bellacosa A: Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways. Oncogene 24: 7443-7454, 2005.
16. Hennessy BT, Smith DL, Ram PT, Lu Y and Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004, 2005.
17. Yang Y, Alcaraz AA and Snyder JP: The tubulin-bound conformation of paclitaxel: T-taxol vs "PTX-NY". J Nat Prod 72: 422-429, 2009.
18. Lee KM, Cao D, Itami A, et al: Class III β-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia. Histopathology 51: 539-546, 2007.
19. Poulain L, Lincet H, Duigou F, et al: Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer 78: 454-463, 1998.
20. Işeri OD, Kars MD, Arpaci F, Atalay C, Pak I and Gündüz U: Drug resistant MCF-7 cells exhibit epithelial-mesenchymal transition gene expression pattern. Biomed Pharmacother 65: 40-45, 2011.
21. Haslehurst AM, Koti M, Dharsee M, et al: EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 12: 91, 2012.
22. Maseki S, Ijichi K, Tanaka H, et al: Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway. Br J Cancer 106: 1196-1204, 2012.
23. Ahmed N, Abubaker K, Findlay J and Quinn M: Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 10: 268-278, 2010.
24. Brabletz T, Jung A, Spaderna S, Hlubek F and Kirchner T: Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat Rev Cancer 5: 744-749, 2005. of Education of China